Vav2/ Rac1 status after transplantation into syngenic, lethally irradiated recipients (median survival 38 ± 3 days). However, that was concordant with a very recent study 14 published during preparation of this manuscript that showed that Rac2 rather than Rac1 influences leukemia latency. Indeed Rac2-GTP levels in HOX-transformed cells did not correlate with the vav2 status (not shown). Only the spleen weight of the diseased animals was significantly different in vav2 À / À transplants (270±64 mg, mean ± s.d., n ¼ 7) compared with wild-type (349 ± 83 mg, n ¼ 7, P ¼ 0.04) and VAV2-complemented cells (399 ± 70 mg, n ¼ 5, P ¼ 0.004), indicating potentially altered engraftment behavior of vav2 À / À cells. In summary, here we describe a potential method how to prioritize the large numbers of HOX-controlled genes in order to search for targets with increased biological relevance in HSPC. We validated this approach by identifying Vav2 and therefore Rac1 activity to be under HOX control. Rac1, a member of the Rho superfamily of small GTPases, is widely involved in hematopoietic development and it is particularly important for control of HSPC-specific properties such as engraftment and homing, as well as for proper interaction with the microenvironment.
Mutations in the DNMT3A exon 23 independently predict poor outcome in older patients with acute myeloid leukemia: a SWOG report Leukemia (2013) 27, 238-241; doi:10.1038/leu.2012.168
Acute myeloid leukemia (AML) represents a heterogeneous group of malignancies with great variability in clinical course and response to therapy. Currently, cytogenetics is the single most important prognostic factor in this disease. In recent years, an increasing number of molecular features with prognostic significance in AML have been identified. [1] [2] [3] DNA cytosine-5-methyltransferase 3A (DNMT3A) encodes an enzyme that catalyzes the addition of a methyl group to the cytosine residue of CpG dinucleotides. By regulating the methylation of clusters of CpG, this enzyme mediates the downregulation of downstream genes. Recent studies using large-scale arraybased genomic resequencing and whole-genome sequencing of human leukemia uncovered recurrent mutations in this gene in AML patients. 4, 5 Subsequent studies demonstrated that these Accepted article preview online 22 June 2012; advance online publication, 13 July 2012 Letters to the Editor mutations are independently associated with decreased survival in adult AML patients. [5] [6] [7] [8] [9] [10] [11] As the previous studies included mostly young AML patients, currently there is a paucity of information regarding the prognostic value of these newly identified mutations in the older AML population. Thus, we studied the incidence and prognostic impact of these mutations in the context of other prognostic markers in a cohort of uniformly treated older patients with AML. Pretreatment samples were obtained from patients with AML enrolled in the SWOG clinical trials S-9031 and S-9333. All patients enrolled in these studies were 455 years old and had untreated AML. A total of 234 and 334 patients were registered for S-9031 and S-9333 trials, respectively. Details of the treatment protocols have been previously reported. 12, 13 In brief, in the S-9031 trial, the patients were randomly assigned to a standard induction regimen (daunorubicin 45 mg/m 2 /day for 3 days and Ara-C 200 mg/m 2 /day for 7 days) plus either placebo or G-CSF (400 mg/m 2 once daily). In the S-9333 trial, the patients were randomized to receive mitoxantrone (10 mg/m 2 /day for 5 days) and etoposide (100 mg/ m 2 /day for 5 days), or standard induction regimen. Patients with acute promyelocytic leukemia were excluded, as were SWOG-9333 patients randomized to induction chemotherapy with mitoxantrone and etoposide, as this is not currently a standard therapy. At the time of diagnosis, samples were analyzed in SWOG-approved laboratories for cytogenetic abnormalities using standard techniques. Cytogenetic abnormalities were grouped according to published criteria.
14 Written informed consent was obtained for all patients according to the Declaration of Helsinki, and the institutional review boards of member sites approved the studies.
As previous studies consistently showed that the majority of mutated DNMT3A (DNMT3A þ ) are located in exon 23, we amplified this exon bypolymerase chain reaction, and sequenced as previously described. 15 Other relevant genes were assessed for frequently occurring mutations as previously described (that is, NPM1, FLT3 internal tandem duplication (FLT3-ITD), CEBPA and IDH1/2). [1] [2] [3] 15 Genomic DNA extracted from diagnostic specimens from 191 patients were available for evaluation. In all, 80% (153 out of 191) were de novo and 20% (38 out of 191) were secondary AML cases. The source of the DNA was bone marrow in the case of 86.4% of the samples and peripheral blood in the case of 13.6%.
Missense mutations of DNMT3A exon 23 were identified in 37 patients (19%). A total of six different mutations were identified: R882H (n ¼ 20), R882C (n ¼ 13), R887I (n ¼ 1), L901R (n ¼ 1), P903L (n ¼ 1) and C911Y (n ¼ 1). Characteristics of patients with and without DNMT3A þ were compared (Table 1 ). There were no statistically significant differences in the median age, sex, white blood cell (WBC) count, blast percentage, hemoglobin, platelet count or French-American-British (FAB) classification and ECOG (Eastern Cooperative Oncology Group) performance scores at diagnosis between DNMT3A þ and DNMT3A wild type (WT). There was no statistically significant difference in the incidence of DNMT3A þ among de novo and secondary AML (P ¼ 0.82). NPM1 mutations (NPM1 þ ) were more common among DNMT3A þ than in DNMT3A-WT patients (65% vs 26%, Po0.0001). There were no significant differences in the incidence of FLT3-ITD, CEBPA or IDH1/2 mutations among patients with DNMT3A
þ as compared with DNMT3A-WT. Patients with normal cytogenetics were then subdivided into high (presence of FLT3-ITD regardless of NPM1 status or the absence of FLT3-ITD and NPM1-WT)-and low (absence of FLT3-ITD and NMP1-mutated or CEPBA-mutated)-molecular-risk groups. 16 A greater proportion of DNMT3A þ patients were low risk as compared with DNMT3A-WT patients (46% vs 14%), whereas, comparably, a smaller proportion of DNMT3A þ patients were high risk as compared with DNMT3A-WT patients (54% vs 86%, Po0.001).
Clinical outcome data were examined for all patients with DNMT3A þ and DNMT3A-WT. The median follow-up time for patients who remained alive was 8.3 years. Patients with
DNMT3A
þ or DNMT3A-WT had similar complete remission rates (odds ratio ¼ 1, 95% confidence interval, 0.5, 2.1, P ¼ 0.98). The overall survival (OS) at 2 years from study entry for DNMT3A þ patients was 11% vs 21% for those with DNMT3A-WT (P ¼ 0.065). For patients with DNMT3A þ or DNMT3A-WT, 2-year event-free survival (EFS) and relapse-free survival (RFS) were 3% vs 16% Letters to the Editor (P ¼ 0.043) and 8% vs 26% (P ¼ 0.23), respectively. In multivariate Cox proportional hazards regression analyses after adjusting for other known prognostic factors such as age, ECOG performance status, WBC, blast count, cytogenetic risk groups, FLT3-ITD and NPM1 mutation status, the presence of DNMT3A þ was independently associated with worse OS, EFS and RFS (Supplementary  Table S1 and Supplementary Figure S1) .
The prognostic impact of the DNMT3A þ was evaluated in specific cytogenetic risk groups. CN (cytogenetically normal)-AML was more common among DNMT3A þ patients as compared with DNMT3A-WT patients (75% vs 42%, P ¼ 0.003). DNMT3A þ were not observed in patients with core binding factor (CBF) AML and were rare in those with high-risk cytogenetics. In patients with CN-AML, DNMT3A þ was associated with worse OS (2-year, 10% vs 31%, P ¼ 0.0078), EFS (2-year 0% vs 27%, P ¼ 0.0014) and RFS (2-year 8% vs 39%, P ¼ 0.0073) as compared with patients with DNMT3A-WT. In multivariate analysis among CN-AML, DNMT3A þ patients had worse OS, EFS and RFS as compared withthose with DNMT3A-WT (Supplementary Table S2 and Supplementary Figure S2 ).
The patients with normal cytogenetics were then subdivided into high-and low-molecular-risk groups. Among the high-risk subgroup, OS was significantly worse in the DNMT3A þ patients (2-year 0% vs 22%, P ¼ 0.02) as were the EFS (2-year 0% vs 16%, P ¼ 0.033) and RFS (2-year 0% vs 25%, P ¼ 0.02). In the low-risk subgroup, there was no statistically significant difference between DNMT3A þ and DNMT3A-WT in the OS (25% vs 30%, P ¼ 0.29), EFS (8% vs 30%, P ¼ 0.29) or RFS (50% vs 31%, P ¼ 0.22) (Figure 1) . In this study, we demonstrate that in older adults with AML mutations in the exon 23 of DNMT3A gene are common, and their presence is highly associated with normal cytogenetics and with adverse clinical outcome. We further demonstrate that within the high-risk molecular cohort, presence of DNMT3A þ provides further prognostic demarcation; where in the molecular high-risk cohort, those with DNMT3A þ have a dismal outcome. These findings are consistent with the observations made in younger AML patients, highlighting the fact that DNMT3A þ can be used to refine risk stratification in high-risk cohort of patients.
Other investigators recently reported on the negative prognostic impact of DNMT3A þ in elderly AML patients. 17, 18 Similar to our study and that by others, [5] [6] [7] [8] [9] [10] [11] Marcucci et al. 17 also found that mutations affecting arginine codon 882 (R882) were more common than those affecting other codons (non-R882). Interestingly, the investigators also observed that the prognostic significance of DNMT3A þ depended on the type of mutation. In younger patients, only non-R882-DNMT3A þ were associated with worse clinical outcome, whereas R882-DNMT3A þ had no prognostic significance. Conversely, in older patients, only R882-DNMT3A þ were independently associated with worse outcome. The reasons why the prognostic significance of different DNMT3A þ types varies in younger and older patients are currently unknown. 17 Previous studies have shown that the majority of mutations in DNMT3A are located in the functional methyltransferase domain (exon 23). [5] [6] [7] With currently available clinical assays, screening of the entire DNMT3A is not feasible. It is important to note that by limiting mutation analysis to the functional 'hot spot' of this gene, although a practical approach for the purpose of risk stratification, and to aid in clinical decision-making, B15-20% of the mutations located outside the methyltransferase domain are missed.
As shown in younger adult AML patients, we also found in this cohort of older AML patients that DNMT3A þ can identify risk subgroups in the high-risk cohort, whereas in the low-risk group DNMT3 þ have no prognostic effect. 7 Although this has been consistently demonstrated in previous studies, the reason for these findings is unclear. It is conceivable that cooperating genetic and epigenetic alterations may lead to a distinct leukemic phenotype and enhanced drug resistance. Moreover, because of the higher prevalence of DNMT3A þ in CN-AML, the clustering of certain mutations (NPM1, FLT3-ITD and IDH1/2) and the strong selection against CBF abnormalities are likely not random and it would be important to determine whether mutations in these genes have overlapping or cooperating functional consequences.
Our study shows that DNMT3A þ have high prevalence and an independently negative prognostic impact on older patients with AML, although the findings must be interpreted cautiously as they are based on a relatively small cohort, and the mutation analysis was limited to the functional 'hot spot' of the gene. DNMT3A can be identified as a potentially important molecular marker for elderly patients, especially those with CN-AML. Moreover, within the high-risk molecular group, DNMT3A þ identifies a subset of patients with especially poor prognosis. These findings are likely to have a major impact on the clinical management of AML, as these genetic alterations may not only represent a prognostic marker but may also constitute targets for therapeutic intervention, which are especially needed in older AML patients. Mutation profiling of DNMT3A exon 23 can easily be incorporated into clinical practice to aid in risk-based therapy allocation. In addition, this high-risk cohort may provide a target population for assessment of novel epigenetic modifying agents.
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